Kytril
(Granisetron)ApprovedSmall molecule
Granisetron is used to prevent nausea and vomiting caused by cancer chemotherapy treatments and surgery. It works by blocking signals in the brain that trigger nausea.[2] Kytril is currently approved and in use across 12 indications[4].[1]
Kytril is one of 232 small molecule programs targeting Cervical Cancer. It is currently in Approved.
12
Indications
54
Total Trials
5
Active Trials
231
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
265 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Kytril
CConrado Roberto Hoffmann Filho
Approved
Ibrance
PfizerPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Hepsera
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Doptelet
AAkarx
Preclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nausea and vomiting12 trials
A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA
Completed·—·Phase 3·NCT04918862·210 enrolled
Show 9 more trials
Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery
Unknown status·—·Phase 4·NCT05632224·60 enrolled
Chemotherapy-induced nausea and vomiting4 trials
Cesarean Section3 trials
The Effect of Intravenous Granisetron and Ondansetron in Patients Undergoing Cesarean Section
Completed·—·Phase 3·NCT04613726·120 enrolled
Effect of Granisetron on Morphine Induced Pruritus in Cesarean Section
Completed·—·Phase 2·NCT03483870·80 enrolled
Chemotherapy3 trials
Laparoscopic Cholecystectomy2 trials
Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy
Unknown status·—·Phase 4·NCT04899817·60 enrolled
Granisetron Combined With Dexamethasone or Metoclopramide for PONV Prevention After Laparoscopic Cholecystectomy
Not yet recruiting·—·Phase 4·NCT07360431·102 enrolled
27 more indications
Prevention2 trials
Prevention of Spinal Induced Shivering During CS
Completed·—·Phase 2·NCT02588547·212 enrolled
Tics2 trials
Cesarean Delivery1 trial
Fasting Conditions1 trial
Vomiting1 trial
Intravenous1 trial
Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients
Completed·—·Phase 2·NCT00450853·31 enrolled
Vaginal Cancer1 trial
Interaction1 trial
Malignant Glioma1 trial
Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients
Withdrawn·—·Phase 2·NCT01952886
Efficacy and Safety1 trial
Single Dose1 trial
Temporomandibular Disorders1 trial
Patient-Controlled Analgesia1 trial
Effectiveness1 trial
Midazolam1 trial
Comp Granisetron Midazolam Comb in Lap Children
Unknown status·—·Phase 3·NCT03483350·90 enrolled
Regulatory
FDA Approval Timeline[5]
Mar 16, 1995
KYTRIL
NDA NDA020305
Jun 27, 2001
KYTRIL
NDA NDA021238
Sep 17, 2004
KYTRIL
NDA NDA020239
Sep 12, 2008
SANCUSO
NDA NDA022198
Aug 9, 2016
SUSTOL
NDA NDA022445
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Kytril drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Granisetron. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serotonin 3a (5-Ht3a) Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- CConrado Roberto Hoffmann Filho